Logo image of AAPG

ASCENTAGE PHARMA GR-ADR (AAPG) Stock Fundamental Analysis

NASDAQ:AAPG - Nasdaq - ADR - Currency: USD

26.295  +0.8 (+3.12%)

Fundamental Rating

3

Taking everything into account, AAPG scores 3 out of 10 in our fundamental rating. AAPG was compared to 568 industry peers in the Biotechnology industry. Both the profitability and financial health of AAPG have multiple concerns. AAPG shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year AAPG has reported negative net income.
In the past year AAPG has reported a negative cash flow from operations.
In the past 5 years AAPG always reported negative net income.
In the past 5 years AAPG always reported negative operating cash flow.
AAPG Yearly Net Income VS EBIT VS OCF VS FCFAAPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500M -1B

1.2 Ratios

AAPG's Return On Assets of -11.60% is amongst the best of the industry. AAPG outperforms 86.44% of its industry peers.
AAPG has a Return On Equity of -47.01%. This is in the better half of the industry: AAPG outperforms 66.02% of its industry peers.
Industry RankSector Rank
ROA -11.6%
ROE -47.01%
ROIC N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
AAPG Yearly ROA, ROE, ROICAAPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

AAPG's Gross Margin of 96.96% is amongst the best of the industry. AAPG outperforms 95.77% of its industry peers.
AAPG's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for AAPG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
AAPG Yearly Profit, Operating, Gross MarginsAAPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

AAPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AAPG has more shares outstanding
The number of shares outstanding for AAPG has been increased compared to 5 years ago.
AAPG has a better debt/assets ratio than last year.
AAPG Yearly Shares OutstandingAAPG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AAPG Yearly Total Debt VS Total AssetsAAPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

An Altman-Z score of 1.92 indicates that AAPG is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.92, AAPG is in the better half of the industry, outperforming 72.54% of the companies in the same industry.
AAPG has a Debt/Equity ratio of 1.42. This is a high value indicating a heavy dependency on external financing.
AAPG's Debt to Equity ratio of 1.42 is on the low side compared to the rest of the industry. AAPG is outperformed by 80.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.42
Debt/FCF N/A
Altman-Z 1.92
ROIC/WACCN/A
WACC8.8%
AAPG Yearly LT Debt VS Equity VS FCFAAPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

AAPG has a Current Ratio of 1.84. This is a normal value and indicates that AAPG is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.84, AAPG is not doing good in the industry: 77.11% of the companies in the same industry are doing better.
AAPG has a Quick Ratio of 1.83. This is a normal value and indicates that AAPG is financially healthy and should not expect problems in meeting its short term obligations.
AAPG has a worse Quick ratio (1.83) than 75.88% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.83
AAPG Yearly Current Assets VS Current LiabilitesAAPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.48% over the past year.
Looking at the last year, AAPG shows a very strong growth in Revenue. The Revenue has grown by 341.77%.
Measured over the past years, AAPG shows a very strong growth in Revenue. The Revenue has been growing by 132.25% on average per year.
EPS 1Y (TTM)61.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.78%
Revenue 1Y (TTM)341.77%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%97.9%

3.2 Future

Based on estimates for the next years, AAPG will show a very strong growth in Earnings Per Share. The EPS will grow by 24.96% on average per year.
Based on estimates for the next years, AAPG will show a very strong growth in Revenue. The Revenue will grow by 25.44% on average per year.
EPS Next Y-182.73%
EPS Next 2Y103.09%
EPS Next 3Y24.96%
EPS Next 5YN/A
Revenue Next Year-43.23%
Revenue Next 2Y66.22%
Revenue Next 3Y34.47%
Revenue Next 5Y25.44%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AAPG Yearly Revenue VS EstimatesAAPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AAPG Yearly EPS VS EstimatesAAPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AAPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AAPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AAPG Price Earnings VS Forward Price EarningsAAPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AAPG Per share dataAAPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

AAPG's earnings are expected to grow with 24.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.09%
EPS Next 3Y24.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AAPG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASCENTAGE PHARMA GR-ADR

NASDAQ:AAPG (4/25/2025, 8:00:00 PM)

26.295

+0.8 (+3.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/bmo
Earnings (Next)N/A N/A
Inst Owners7.36%
Inst Owner ChangeN/A
Ins Owners13.63%
Ins Owner ChangeN/A
Market Cap2.29B
Analysts87.14
Price Target23.61 (-10.21%)
Short Float %0%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-10.88%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.48
P/FCF N/A
P/OCF N/A
P/B 21.78
P/tB 25.21
EV/EBITDA N/A
EPS(TTM)-0.62
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS1.42
BVpS1.21
TBVpS1.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.6%
ROE -47.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.96%
FCFM N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 1.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 4.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.83
Altman-Z 1.92
F-Score5
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.78%
EPS Next Y-182.73%
EPS Next 2Y103.09%
EPS Next 3Y24.96%
EPS Next 5YN/A
Revenue 1Y (TTM)341.77%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%97.9%
Revenue Next Year-43.23%
Revenue Next 2Y66.22%
Revenue Next 3Y34.47%
Revenue Next 5Y25.44%
EBIT growth 1Y59.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-258.85%
EBIT Next 3Y-7.51%
EBIT Next 5YN/A
FCF growth 1Y7.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.61%
OCF growth 3YN/A
OCF growth 5YN/A